



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER OF PATENTS AND TRADEMARKS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/992,936	11/05/2001	Robert F. Kaiko	200.1102CP2	9880

23280 7590 05/06/2003

DAVIDSON, DAVIDSON & KAPPEL, LLC  
485 SEVENTH AVENUE, 14TH FLOOR  
NEW YORK, NY 10018

EXAMINER
----------

WARE, TODD

ART UNIT	PAPER NUMBER
----------	--------------

1615

DATE MAILED: 05/06/2003

11

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No.

09/992,936

Applicant(s)

KAIKO ET AL.

Examiner

Todd D Ware

Art Unit

1615

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --  
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 06 February 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1,3,8-10,12-27,29-32 and 35-41 is/are pending in the application.

4a) Of the above claim(s) \_\_\_\_\_ is/are withdrawn from consideration.

- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☐ Claim(s) 1,3,8-10,12-27,29-32 and 35-41 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.  
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- 11) ☐ The proposed drawing correction filed on \_\_\_\_\_ is: a) ☐ approved b) ☐ disapproved by the Examiner.  
If approved, corrected drawings are required in reply to this Office action.
- 12) ☐ The oath or declaration is objected to by the Examiner.

**Priority under 35 U.S.C. §§ 119 and 120**

- 13) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).  
a) ☐ All b) ☐ Some \* c) ☐ None of:  
1. ☐ Certified copies of the priority documents have been received.  
2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.  
3. ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).  
\* See the attached detailed Office action for a list of the certified copies not received.
- 14) ☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).  
a) ☐ The translation of the foreign language provisional application has been received.
- 15) ☒ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892) 4) ☐ Interview Summary (PTO-413) Paper No(s). \_\_\_\_\_
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948) 5) ☐ Notice of Informal Patent Application (PTO-152)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449) Paper No(s) 9, 10. 6) ☐ Other: \_\_\_\_\_

### **DETAILED ACTION**

Receipt of amendment and information disclosure statement both filed 2-6-03 and information disclosure statement filed 3-18-03 is acknowledged. Claims 6-7, 28, and 34 have been canceled and claims 1, 3, 9-10, 12-19, 29, 32 have been amended and new claim 41 has been added as requested. Claims 1, 3, 8-10, 12-27, 29-32 and 35-41 are pending.

#### ***Continued Examination Under 37 CFR 1.114***

1. A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 2-6-03 has been entered.

#### ***Claim Objections***

2. Claims 19, 20 and 27 are objected to under 37 CFR 1.75(c), as being of improper dependent form for failing to further limit the subject matter of a previous claim. Applicant is required to cancel the claim(s), or amend the claim(s) to place the claim(s) in proper dependent form, or rewrite the claim(s) in independent form. Each of these claims depend from claim 1 and require a sustained release carrier that releases the

Art Unit: 1615

opioid agonist over a time period of about 8 to about 24 hours. This is already required in claim 1.

***Claim Rejections - 35 USC § 112***

3. The following is a quotation of the second paragraph of 35 U.S.C. 112:

The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention.

4. Claims 29-30 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

5. Claims 29-30 depend from canceled claim 28 and are therefore indefinite since they are incomplete. For purposes of examination, these claims are examined as depending from claim 1.

***Claim Rejections - 35 USC § 103***

6. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

7. **Claims 1, 3, 6, 8-32, and 34-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Crain et al (5,512,578; hereafter '578) in combination with the Physicians Desk Reference for either Vicodin, Lorcet or Lortab (1995; hereafter PDR) and further in combination with Oshlack et al (5,472,712; hereafter '712).**

Art Unit: 1615

8. The instant claims are directed toward combination opioid agonist/antagonist/acetaminophen controlled release oral formulations and a method for treating pain with the combination opioid agonist/antagonist/acetaminophen oral formulations.

9. '578 teaches oral compositions comprising opioid agonists and opioid antagonists that may be used for treating opioid abuse. '578 also teaches a method treating pain with the disclosed composition. '578 does not teach the inclusion of non-narcotic analgesics in the disclosed formulation or a controlled release formulation.

10. The PDR is relied upon for teaching inclusion of non-narcotic analgesics, such as acetaminophen in narcotic formulations for the treatment of pain. It does not teach controlled release formulations as required in the instant claims.

11. '712 teaches controlled release opioid formulations that provide controlled release in accordance with the instant claims.

12. Accordingly, it would have been obvious to one skilled in the art at the time of the invention to include non-narcotic analgesics in the formulation of '578 in an effort to provide enhanced analgesia by means of producing analgesia through non-opioid antinociceptive pathways. Furthermore, it would have been obvious to one skilled in the art at the time of the invention to use an opioid dose that would otherwise be subtherapeutic if given alone with the motivation of maintaining low instance of side effects while maintaining an analgesic effectiveness. It would also have been obvious to one skilled in the art at the time of the invention to provide controlled release

Art Unit: 1615

formulations of the obvious previous compositions to reduce the frequency of administration.

***Response to Arguments***

13. Applicant's arguments filed 2-6-03 have been fully considered but they are not persuasive. Applicant argues that the consisting essentially language excludes inclusion of active agents other than those recited in the claims and therefore overcomes the previous rejections. Applicant's arguments have been considered but are moot in view of the new ground(s) of rejection.

14. **Claims 1, 3, 6, 8-32, and 34-40 are rejected under 35 U.S.C. 103(a) as being unpatentable over Gordon et al (4,457,933; hereafter '933) in combination with the Physicians Desk Reference for either Vicodin, Lorcet or Lortab (1995; hereafter PDR) and further in combination with Oshlack et al (5,472,712; hereafter '712).**

15. '933 teaches opioid agonist and opioid antagonist composition and methods for treating pain. '933 does not teach inclusion of non-narcotic analgesics or a controlled release formulation in the taught formulations.

16. The PDR is relied upon for teaching inclusion of non-narcotic analgesics, such as acetaminophen in narcotic formulations for the treatment of pain. It does not teach controlled release formulations as required in the instant claims.

17. '712 teaches controlled release opioid formulations that provide controlled release in accordance with the instant claims.

18. Accordingly, it would have been obvious to one skilled in the art at the time of the invention to include non-narcotic analgesics in the formulation of '578 in an effort to provide enhanced analgesia by means of producing analgesia through non-opioid antinociceptive pathways. Furthermore, it would have been obvious to one skilled in the art at the time of the invention to use an opioid dose that would otherwise be subtherapeutic if given alone with the motivation of maintaining low instance of side effects while maintaining an analgesic effectiveness. It would also have been obvious to one skilled in the art at the time of the invention to provide controlled release formulations of the obvious previous compositions to reduce the frequency of administration.

***Response to Arguments***

19. Applicant's arguments filed 2-6-03 have been fully considered but they are not persuasive. Applicant argues that the consisting essentially language excludes inclusion of active agents other than those recited in the claims and therefore overcomes the previous rejections. Applicant's arguments have been considered but are moot in view of the new ground(s) of rejection.

20. **Claim 41 is rejected under 35 U.S.C. 103(a) as being unpatentable over Crain et al (5,512,578; hereafter '578) in view of the Physicians Desk Reference for either Vicodin, Lorcet or Lortab (1995; hereafter PDR) OR Gordon et al (4,457,933; hereafter '933) in combination with the Physicians Desk Reference for either Vicodin, Lorcet or Lortab (1995; hereafter PDR) .**

21. The instant claims are directed toward combination opioid agonist/antagonist/acetaminophen oral formulations and a method for treating pain with them.
22. '578 and '933 teach oral compositions comprising opioid agonists and opioid antagonists that may be used for treating opioid abuse and treating pain. Neither reference teaches inclusion of non-narcotic analgesics in the disclosed formulation.
23. The PDR is relied upon for teaching inclusion of non-narcotic analgesics, such as acetaminophen in narcotic formulations for the treatment of pain. It does not teach controlled release formulations as required in the instant claims.
24. Accordingly, it would have been obvious to one skilled in the art at the time of the invention to include non-narcotic analgesics in the formulation of '578 or '933 to provide enhanced analgesia by means of producing analgesia through non-opioid antinociceptive pathways. Furthermore, it would have been obvious to one skilled in the art at the time of the invention to use an opioid dose that would otherwise be subtherapeutic if given alone with the motivation of maintaining low incidence of side effects while maintaining an analgesic effectiveness.

### ***Double Patenting***

25. The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the "right to exclude" granted by a patent and to prevent possible harassment by multiple assignees. See *In re Goodman*, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); *In re Longi*, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); *In re Van Ornum*, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); *In re Vogel*, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); and, *In re Thorington*, 418 F.2d 528, 163 USPQ 644 (CCPA 1969).



Art Unit: 1615

A timely filed terminal disclaimer in compliance with 37 CFR 1.321<sup>©</sup> may be used to overcome an actual or provisional rejection based on a nonstatutory double patenting ground provided the conflicting application or patent is shown to be commonly owned with this application. See 37 CFR 1.130(b).

Effective January 1, 1994, a registered attorney or agent of record may sign a terminal disclaimer. A terminal disclaimer signed by the assignee must fully comply with 37 CFR 3.73(b).

26. Claims 1, 3, 8-10, 12-27, 29-32 and 35-41 are rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-50 of U.S. Patent No. 6,277,384. Although the conflicting claims are not identical, they are not patentably distinct from each other because both are drawn to methods of use for oral opioid agonist/antagonist compositions. Furthermore, the method of 6,277,384 discloses the compositions of the instant application.

27. Claims 1, 3, 6-32 and 34-40 are provisionally rejected under the judicially created doctrine of obviousness-type double patenting as being unpatentable over claims 1-36 of copending Application No. 09/503,020. Although the conflicting claims are not identical, they are not patentably distinct from each other because both are drawn to methods of use for oral opioid agonist/antagonist compositions. Furthermore, the method of Application No. 09/503,020 discloses the compositions of the instant application.

This is a provisional obviousness-type double patenting rejection because the conflicting claims have not in fact been patented.

***Response to Arguments***

Art Unit: 1615

28. Applicant's arguments filed 8-12-02 have been fully considered but they are not persuasive. Applicant has stated that a terminal disclaimer will be filed upon indication that the claims are otherwise allowable.

**Conclusion**

29. Currently, no claim is allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Todd D Ware whose telephone number is (703) 305-1700. The examiner can normally be reached on M-F, 8:30 AM - 5 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Thurman K Page can be reached on (703)308-2927. The fax phone numbers for the organization where this application or proceeding is assigned are (703) 308-4556 for regular communications and (703) 308-4556 for After Final communications.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the receptionist whose telephone number is (703) 308-1234.

tw  
April 28, 2003

THURMAN K. PAGE  
SUPERVISORY PATENT EXAMINER  
TECHNOLOGY CENTER 1600